Oligonucleotide Pool Market Trends

Global Oligonucleotide Pool Market Overview

The oligonucleotide pool market size was valued at USD 1.53 Billion in 2023. The oligonucleotide pool industry is projected to grow from USD 1.67 Billion in 2024 to USD 3.17 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.30% during the forecast period (2024 - 2032). 

Growing investment in oligonucleotide therapeutics for drug development by big pharmaceutical companies, increased involvement of CMOs in manufacturing therapeutic oligonucleotides, and increasing awareness about cell and gene therapy are the key market drivers enhancing the market growth.

Source Primary Research, MRFR Database, Secondary Research, and Analyst Review

Waters Corporation has introduced OligoWorks SPE (solid-phase extraction) kits and components in October 2023 to enhance the preparation of samples for LC-MS-based bioanalytical quantitation of therapeutic oligonucleotides. The oligonucleotide recovery from biofluids can now be enhanced by up to a twofold over competing products for pharma and biopharma companies that are developing oligonucleotide therapeutics, as well as the Contract Research Organizations (CROs) that support them. The packages provide increased LC-MS sensitivity and reproducibility, which reduces the necessity for repeat experiments and enables lower limits of quantitation. The pipeline for oligonucleotide therapeutics is expanding at a rapid pace, with 13 FDA-approved oligonucleotide therapeutics currently in circulation and over 500 more in the pipeline. 

Although efficacious, these highly modified oligonucleotides are difficult to precisely quantify during dosing, metabolism, and tissue distribution studies. OligoWorks SPE kits also employ an innovative, enzyme-enhanced, and detergent-free sample pretreatment that enables direct injection LC-MS analysis and lower limits of quantitation. This pretreatment reduces the number of rinsing steps and enhances mass spectrometer compatibility. Additionally, they can be entirely automated to enhance productivity or to assist scientists in reclaiming time by minimizing manual steps and oversight.

In November 2023, Twist Bioscience Corporation (NASDAQ: TWST), a company that empowers customers to achieve success by providing high-quality synthetic DNA through its silicon platform, introduced Twist Express Genes, a new, industry-leading gene synthesis service with a five- to seven-business-day turnaround time. Twist utilizes its silicon-based DNA synthesis platform, expertise, software, honed processes, and the expanded layout of its Wilsonville facility to deliver clonal genes and gene fragments at scale and with rapid turnaround times, thereby leveraging its ability to miniaturize the chemical reaction to create DNA. Twist will implement dynamic pricing for Express Genes, charging a premium for speed that is contingent upon market demand and manufacturing capacity. Twist's ecommerce platform will enable customers to place orders for Express Genes. 

The length of Twist Express genes ranges from 0.3 to 5.0 kb. As with standard speed Twist Clonal Genes, Twist Express Genes are NGS sequence-verified as one hundred percent accurate, and orders of any size, big or small, can be filled as a result of the scale facilitated by Twist's platform. Customers can proceed directly to experimentation by cloning Twist Express Genes into catalog vectors or custom vectors. They can also be delivered in the preferred delivery format of the consumer, such as a tube or plate.

Oligonucleotide Pool Market Trends

• Increasing focus on new oligonucleotide therapies is driving the market growth.

Market CAGR for the oligonucleotide pool is being driven by the increasing focus on new oligonucleotide therapies. Pharmaceutical and biotechnological companies are focusing on the R&D of new oligonucleotide drugs due to the presence of a limited number of approved drugs. Oligonucleotides efficiently target disease-relevant proteins and genes inaccessible by small-molecule drugs and biological drugs. Recent advances have helped overcome challenges associated with the administration, cellular uptake, biodistribution, and side effects of oligonucleotide therapies. Many oligonucleotide therapeutics are in various clinical trials to treat many diseases, including viral infections, rare genetic disorders, neural and neuromuscular conditions, and cancers. The presence of these drugs and an increase in R&D are expected to drive the oligonucleotide pool market revenue.

The increasing prevalence of chronic and life-threatening diseases has also prompted pharmaceutical companies and research firms to focus on R&D activities to develop effective therapeutics. As a result, life science research advances are leading to an improved understanding of biological systems. Developing oligonucleotide synthesis technologies has helped pharmaceutical and biotechnology researchers with molecular-level development, design, and modification of biological systems. The increasing research activities in the pharmaceutical and biotechnology sectors will expand the  market.

The emergence of oligonucleotide-based therapies increases the demand for oligonucleotide pool libraries. Oligonucleotides are poly nucleic acids made up of five base pairs called oligos. They work by changing the gene expression of the person they impact. Developing oligonucleotide-based therapies is evolving for various diseases, including respiratory diseases, cancer, influenza, and STDs. Currently, only two oligonucleotide therapeutics are approved by the FDA, namely the antisense oligonucleotide Fomivirsen and the aptamer Macugen. The FDA has authorized several antisense medicines, the majority of which are used to treat rare illnesses such as Batten disease, CMV retinitis, Duchenne muscular dystrophy, and spinal muscular atrophy.

Initiatives taken by key players and government support are also playing a crucial role in the oligonucleotide pool library market growth. Many industry players are working on various strategies for emerging technologies for oligonucleotide pool libraries. The government also supports developing novel therapies based on genes for rare diseases. For instance, in August 2021, The News Agency of Nigeria (NAN) reported that Federal Government is expected to increase research and healthcare development investments to boost the health sector. Under this investment ministry of state, health is expected to inaugurate an oligo-synthesis laboratory.

Oligonucleotide Pool Market Segment Insights

Oligonucleotide Pool Type Insights

The oligonucleotide pool market segmentation, based on type, includes DNA and RNA. The DNA segment dominated the market, accounting for 35% of market revenue (0.54 Billion). In developing economies, category growth is driven by the significant utilization of DNA microarray technology and oligonucleotide for diagnostics therapeutics, and recent microchip-based oligonucleotide synthesis drives the market growth. However, RNA is the fastest-growing category due to the development of nonsensical RNA therapy in emerging economies.

Oligonucleotide Pool Application Insights

The oligonucleotide pool market segmentation, based on application, includes research, diagnostic & therapeutics, and others. The diagnostic & therapeutics category generated the most income (70.4%) due to increasing focus on R&D activities by companies to develop novel diagnostic & therapeutics equipment in emerging economies. However, research is the fastest-growing category owing to the growing research and development activities for developing oligonucleotide pool drugs.

Oligonucleotide Pool End-User Insights

The oligonucleotide pool market segmentation, based on end-user, includes commercial research, pure academic research, and others. The pure academic research category generated the most income due to surging healthcare spending capacity and advancement in healthcare infrastructure. However, commercial research is the fastest-growing category due to rising government investments in synthetic biology and genome projects.

Figure 1 Oligonucleotide Pool Market by End-User, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Oligonucleotide Pool Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American oligonucleotide pool market area will dominate this market, owing to the presence of many market players and various developments done by them is the key factor driving the region's growth. Moreover, technological advancements, high investment in R&D, and rising demand for innovative oligonucleotide pools are other factors supporting the regional market. Further, the US oligonucleotide pool market held the largest market share, and the Canadian oligonucleotide pool market was the fastest-growing market in the European region.

Further, the prominent countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 Oligonucleotide Pool Market Share By Region 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's oligonucleotide pool market accounts for the second-largest market share owing to the growing number of companies operating in the region adopting various strategies, including research initiatives, product launches, and others, to propel the market growth. Further, the German oligonucleotide pool market held the largest market share, and the UK oligonucleotide pool market was the fastest-growing market in the European region.

The Asia-Pacific oligonucleotide pool market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to the presence of a large population and increasing awareness regarding the oligonucleotide pool. Moreover, China’s oligonucleotide pool market held the largest market share, and the Indian oligonucleotide pool market was the fastest-growing market in the Asia-Pacific region.

Oligonucleotide Pool Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the oligonucleotide pool market grow even more. Market participants are also undertaking numerous strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the oligonucleotide pool industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the oligonucleotide pool industry to benefit clients and increase the market sector. Major players in the oligonucleotide pool market, including Agilent Technologies, Creative Biogene, CustomArray, Inc., Integrated DNA Technologies, Inc., MYcroarray, Sigma-Aldrich Co. LLC, and others, are attempting to increase market demand by investing in research and development operations.

Pfizer Inc discovers, develops, manufactures, and commercializes biopharmaceuticals. The company offers products to treat cardiovascular, metabolic and pain conditions, women's health, cancer, inflammation, immune disorders, and rare diseases. It also delivers sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients and contract manufacturing services. Pfizer markets its products through wholesalers, retailers, hospitals, individual delivery offices, clinics, government agencies and pharmacies. It has prominent manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. In January 2021, Pfizer Inc., a pharmaceutical and Biotechnology company, announced that it had invested a total of US$ 120 million in 4 clinical-stage biotech firms, as part of the Pfizer Breakthrough Growth Initiative (PBGI), during the second half of the year 2020.

GSK plc (GSK) is a healthcare company focusing on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for treating diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastrointestinal diseases. GSK's vaccine portfolio covers various diseases, including hepatitis, tetanus, whooping cough, diphtheria, rotavirus and HPV infections, measles, and bacterial meningitis. The firm sells its products through wholesalers, pharmacies, hospitals, physicians and other groups ly. In June 2022, GSK plc announced an approximately US$ 1.08 million investment over ten years to accelerate research and development (R&D) activities for infectious diseases that disproportionately impact lower-income countries.

Key Companies in the Oligonucleotide Pool market include

• Agilent Technology (United States)


• Eurogentec S.A (Belgium)


• Merck Group (Germany)


• Illumnia Inc. (United States)


• LGC Biosearch Technologies (United States)


• Eurofins Genomics (Germany)


• Roche Sequencing (United States)


• Integrated DNA Technologies (United States)


• Nitto Denko Avecia Inc (United States)


• General Biosystems (United States)

Oligonucleotide Pool Industry Developments

November 2022: Celerion, a clinical research organization (CRO), expanded its molecular and cellular capabilities to Good Laboratory Practice/Good Clinical Practice standards to help the development of new modality therapies, such as cell and gene therapies. The expanded service offering is available in the company's locations, i.e., Lincoln and Zürich bioanalytical laboratories, including ELISpot analysis, flow cytometry, and qPCR.

July 2022: Eurofins Discovery acquired a contract research organization, DiscoveryBioMed, a life sciences and biotechnology company. This acquisition contributed to Eurofins Discovery's aim of offering various drug discovery services and products.

February 2021: The Centre for Process Innovation introduced an assignment in Medicine Manufacturing Innovation Centre in the UK. Via a partnership with AstraZeneca, Novartis, Exactmer, and UK Research & Innovation, this project seeks to change the synthesis of oligonucleotides. As a result of this contract, inclisiran, a small interfering RNA used to treat atherosclerotic cardiovascular disease (ASCVD), would be the first drug developed on a commercial scale

Oligonucleotide Pool Market Segmentation

Oligonucleotide Pool Type Outlook

• DNA


• RNA

Oligonucleotide Pool Application Outlook

• Research


• Diagnostic & Therapeutics


• Others

Oligonucleotide Pool End-User Outlook

• Commercial Research


• Pure Academic Research


• Others

Oligonucleotide Pool Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America.